Joseph Aaron Sliman MD
Public Health & General Preventive Medicine
Physician
Join to View Full Profile
1 Medimmune WayGaithersburg, MD 20878
Phone+1 301-398-5222
Fax+1 301-398-7867
Dr. Sliman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins Bloomberg School of Public HealthResidency, Public Health and General Preventive Medicine, 2002 - 2004
National Capital ConsortiumInternship, Transitional Year, 1998 - 1999
Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1998
Certifications & Licensure
MD State Medical License 1999 - 2025
Clinical Trials
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children Start of enrollment: 2008 Oct 01
Publications & Presentations
PubMed
- 52 citationsUse of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-contr...John F. Kokai-Kun, Tracey M. Roberts, Olivia Coughlin, Chenxiong (Charles) Le, Heidi Whalen
The Lancet. Infectious Diseases. 2019-05-01 - 51 citationsThe Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.John F. Kokai-Kun, Tracey Roberts, Olivia Coughlin, Eric Sicard, Marianne Rufiange
Antimicrobial Agents and Chemotherapy. 2017-03-01 - 51 citationsDevelopment of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.Michael Kaleko, J. Andrew Bristol, Steven Hubert, Todd Parsley, Giovanni Widmer
Anaerobe. 2016-10-01
Press Mentions
Synthetic Biologics' SYN-004 (Ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. Difficile Infection (CDI)January 5th, 2017- Synthetic Biologics Expands Clinical & Regulatory Leadership Team with Addition of Klaus Gottlieb, MD, FACGJune 2nd, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
